JP2016512505A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512505A5
JP2016512505A5 JP2016500933A JP2016500933A JP2016512505A5 JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5 JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016500933 A JP2016500933 A JP 2016500933A JP 2016512505 A5 JP2016512505 A5 JP 2016512505A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
phenyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016500933A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427551B2 (ja
JP2016512505A (ja
Filing date
Publication date
Priority claimed from US14/200,055 external-priority patent/US9050345B2/en
Application filed filed Critical
Publication of JP2016512505A publication Critical patent/JP2016512505A/ja
Publication of JP2016512505A5 publication Critical patent/JP2016512505A5/ja
Application granted granted Critical
Publication of JP6427551B2 publication Critical patent/JP6427551B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016500933A 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン Expired - Fee Related JP6427551B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US61/775,731 2013-03-11
US14/200,055 2014-03-07
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors
PCT/US2014/022265 WO2014143610A1 (en) 2013-03-11 2014-03-10 Pyrrolotriazines as potassium ion channel inhibitors

Publications (3)

Publication Number Publication Date
JP2016512505A JP2016512505A (ja) 2016-04-28
JP2016512505A5 true JP2016512505A5 (enExample) 2017-04-13
JP6427551B2 JP6427551B2 (ja) 2018-11-21

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500933A Expired - Fee Related JP6427551B2 (ja) 2013-03-11 2014-03-10 カリウムイオンチャネル阻害剤としてのピロロトリアジン

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2858987T (lt) * 2012-06-11 2018-07-10 Bristol-Myers Squibb Company Fosforamido rūgšties provaistai iš 5-[5-fenil-4-(piridin-2-ilmetilamino)chinazolin-2-il]piridin-3-sulfonamido
JP6386527B2 (ja) 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのピロロピリダジン
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company TGFβ受容体アンタゴニスト
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
US10577382B2 (en) * 2016-04-28 2020-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
IL315733A (en) 2022-04-08 2024-11-01 SHY Therapeutics LLC Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases
AR129299A1 (es) 2022-05-11 2024-08-07 Foghorn Therapeutics Inc Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
WO2024088343A1 (zh) * 2022-10-28 2024-05-02 上海深势唯思科技有限责任公司 一种芳基杂环类Kv1.3抑制剂及其制备方法和用途
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2026019945A1 (en) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2026025999A1 (zh) * 2024-08-01 2026-02-05 浙江海正药业股份有限公司 6,7-二氢-5H-吡咯并[1,2-a]咪唑类衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
GEP20063915B (en) * 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
JP2006516653A (ja) 2003-02-05 2006-07-06 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤ピロロトリアジンの製造方法
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
KR20070058602A (ko) 2004-09-30 2007-06-08 티보텍 파마슈티칼즈 리미티드 Hcv 저해 바이-사이클릭 피리미딘
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20080107408A (ko) 2006-03-07 2008-12-10 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
AR060061A1 (es) 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
HRP20140688T1 (hr) * 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
JP2011513419A (ja) 2008-03-06 2011-04-28 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
CN102245610B (zh) * 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
EA021113B1 (ru) * 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
LT2858987T (lt) * 2012-06-11 2018-07-10 Bristol-Myers Squibb Company Fosforamido rūgšties provaistai iš 5-[5-fenil-4-(piridin-2-ilmetilamino)chinazolin-2-il]piridin-3-sulfonamido

Similar Documents

Publication Publication Date Title
JP2016512505A5 (enExample)
JP2016514129A5 (enExample)
JP2016512504A5 (enExample)
JP2016516691A5 (enExample)
JP2014015465A5 (enExample)
JP2016006118A5 (enExample)
JP2014507455A5 (enExample)
JP2019034943A5 (enExample)
JP2015500843A5 (enExample)
JP2016534134A5 (enExample)
JP2013537203A5 (enExample)
JP2015537015A5 (enExample)
JP2016517417A5 (enExample)
JP2016505512A5 (enExample)
JP2016531126A5 (enExample)
JP2015512931A5 (enExample)
JP2016506960A5 (enExample)
JP2017517538A5 (enExample)
JP2020527175A5 (enExample)
JP2014506907A5 (enExample)
JP2016500661A5 (enExample)
JP2016528273A5 (enExample)
JP2012532112A5 (enExample)
JP2016515560A5 (enExample)
JP2017514855A5 (enExample)